FRUZAQLA™ (fruquintinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
ALUNBRIG® (brigatinib) is indicated for the treatment of adult patients with
anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as
detected by an FDA-approved test.
Important Information About EXKIVITY® (mobocertinib)
On October 2, 2023, Takeda announced the initiation of a voluntary withdrawal of EXKIVITY (mobocertinib) 40 mg capsules, for oral use, from the market in the United States (U.S.). This decision was made in consultation with the US Food and Drug Administration (FDA).
EXKIVITY is not being withdrawn immediately and we want to emphasize Takeda’s commitment to ensuring patients who are currently receiving EXKIVITY can maintain access as appropriate and in consultation with their healthcare provider. Patients currently on treatment should consult with their healthcare provider for more information. Takeda will be following up with prescribers and patients with updates when and as appropriate to keep you informed. Updates will also be available at www.exkivity-update.com.
NINLARO® (ixazomib) is indicated in combination with lenalidomide and dexamethasone
for the treatment of patients with multiple myeloma who have received at least one prior
Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly
diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of
controlled clinical trials.
VELCADE® (bortezomib) is approved for the treatment of adults with multiple myeloma (a
cancer of the plasma cells). VELCADE is also approved for the treatment of adults with mantle
cell lymphoma (a cancer of the lymph nodes).